Business of Cannabis / Press Release
SOMAÍ Pharmaceuticals, a leading EU-GMP vertically integrated Multi-Country Operator (MCO) specializing in cannabinoid-based medicines, is proud to announce its entry into Switzerland through a strategic partnership with Dascoli Pharma AG, a Switzerland-based pharmaceutical company specializing in the supply, distribution, and professional training of medical cannabis. This collaboration marks a significant step in ensuring Swiss patients and healthcare professionals have access to high-quality, pharmaceutical-grade medical cannabis extracts, with plans to expand the product offering in the near future.
With Switzerland’s evolving regulatory landscape and growing demand for cannabinoid-based therapies, the partnership between SOMAÍ Pharmaceuticals and Dascoli Pharma AG marks a significant step in expanding medical cannabis access. SOMAÍ will introduce its EU-GMP full-spectrum Essentials line extracts, formulated from single-strain, full-bud flower to ensure pharmaceutical-grade purity, consistency, and efficacy. Designed to meet the highest European standards, these extracts provide precisely dosed and clinically supported treatment options, addressing the needs of both patients and healthcare professionals in Switzerland and beyond.
Michael Sassano, CEO of SOMAÍ Pharmaceuticals, emphasized the significance of the company’s latest expansion, stating: “With our continued entry into new global markets like Switzerland, SOMAÍ is further solidifying its role as a leader in the cannabis pharmaceutical sector. By maintaining our focus on quality, innovation, and accessibility, we are helping shape the future of cannabinoid-based medicine.”
Andrew Petronanos, Founder & CEO of Dascoli Pharma AG, also highlighted the strength of this partnership, saying: “With SOMAÍ’s scientifically advanced extract portfolio and our expertise in Swiss pharmaceutical distribution and education, this collaboration will help improve patient access, enhance industry standards, and contribute to the ongoing evolution of medical cannabis in Switzerland.”
Switzerland is the latest addition to SOMAÍ’s expanding global footprint, reinforcing its position as a leader in cannabinoid-based pharmaceuticals. The company is already commercially active in the United Kingdom, Germany, and Australia, with Ireland and Poland set to launch in 2025.
